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Abstract: Gut microbiota appears to be involved in the pathogenesis of primary sclerosing cholangitis
(PSC). The protein tyrosine phosphatase nonreceptor 2 (PTPN2) gene risk variant rs1893217 is
associated with gut dysbiosis in inflammatory bowel disease (IBD), and PTPN2 was mentioned
as a possible risk gene for PSC. This study assessed the microbial profile of ulcerative colitis (UC)
patients with PSC and without PSC (non-PSC). Additionally, effects of the PTPN2 risk variant were
assessed. In total, 216 mucosal samples from ileum, colon, and rectum were collected from 7 PSC and
42 non-PSC patients, as well as 28 control subjects (non-IBD). The microbial composition was derived
from 16S rRNA sequencing data. Overall, bacterial richness was highest in PSC patients, who also
had a higher relative abundance of the genus Roseburia compared to non-PSC, as well as Haemophilus,
Fusobacterium, Bifidobacterium, and Actinobacillus compared to non-IBD, as well as a lower relative
abundance of Bacteroides compared to non-PSC and non-IBD, respectively. After exclusion of patients
with the PTPN2 risk variant, Brachyspira was higher in PSC compared to non-PSC, while, solely in
colon samples, Eubacterium and Tepidimonas were higher in PSC vs. non-IBD. In conclusion, this study
underlines the presence of gut mucosa-associated microbiome changes in PSC patients and rather
weakens the role of PTPN2 as a PSC risk gene.
Keywords: PSC; PTPN2; TCPTP; mucosa-associated microbiome; Roseburia; Tepidimonas; Actinobacillus;
Haemophilus; Fusobacterium; Brachyspira; Eubacterium
1. Introduction
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease causing intra-
and extrahepatic bile duct strictures and fibrosis, which ultimately leads to liver cirrho-
sis [1,2]. PSC is often associated with ulcerative colitis (UC), affecting roughly 4% of all UC
patients [3–5]. While the exact pathogenesis of PSC remains largely unknown, UC is the
main risk factor, with 60–80% of PSC patients suffering from concurrent UC [4,6–8].
In recent years, changes in the microbiome, metabolome, and intestinal barrier func-
tion were extensively studied to unravel the pathogenesis of PSC [9]. This system is often
referred to as “gut–liver axis”, which symbolizes the interaction of gut microbiota and the
liver: Intestinal dysbiosis, i.e., the change in the microbiota linked to disease, may weaken
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the intestinal barrier and lead to translocation of harmful bacterial particles, which in the
end leads to liver inflammation and fibrosis. It is thought that intestinal dysbiosis in PSC
patients with UC leads to translocation of pathogenic microbes or their products, which
not only cause liver inflammation, but also biliary strictures [10–13]. Studies investigating
changes in the fecal microbiota showed a distinctly different bacterial composition in PSC
patients compared to healthy controls and UC patients [14–16], with certain bacterial taxa
such as Fusobacterium associated with intestinal inflammation, and taxa such as Enterococcus
rather associated with cholangitis [17]. This suggests a strong link between the composition
of the gut microbiome and the pathogenesis of UC and PSC, respectively. Only few studies
with inconsistent findings investigated the mucosa-associated microbiome in PSC [18].
Furthermore, changes in the gut microbiota profile resulting in altered bile acid homeostasis
and increased intestinal inflammation contribute to the pathogenesis of PSC [19,20].
A dysfunction of protein tyrosine phosphatase nonreceptor 2 (PTPN2), caused by the
single nucleotide polymorphism (SNP) rs1893217, is associated with intestinal dysbiosis
and a more severe disease course in inflammatory bowel disease (IBD) patients [21–23].
While the homozygous mutation of PTPN2 occurs in roughly 1.5% of the normal population,
it is present in 3.8% of IBD patients [24]. PTPN2 has also been discussed as a risk gene for
PSC [25]. However, it remains elusive whether this SNP is also associated with intestinal
dysbiosis in PSC patients as reported in IBD patients.
We hypothesized that the presence of PTPN2 SNP rs1893217 is associated with in-
testinal dysbiosis in PSC patients. To this aim, the study compared the mucosa-associated
microbiota of UC patients with and without PSC according to the presence of the PTPN2
SNP, in reference to a control group, by analyzing mucosal biopsies from multiple intestinal
locations from UC patients of the Swiss IBD Cohort (SIBDCS) and a (local) Bern cohort.
2. Materials and Methods
Sample dataset: This study analyzed biopsies from the terminal ileum, the right
colon, the left colon, and the rectum collected during ileocolonoscopies, as published
previously [26]. The SIBDCS comprises primarily IBD patients, who may simultaneously
suffer from PSC, which is a rare liver disease. Therefore, data from seven UC patients
with PSC (PSC) could be retrieved from the SIBDCS. A total of 42 UC patients without
PSC (non-PSC) and 28 controls (non-IBD) were selected based on matching age, gender,
and Modified Truelove and Witts activity index (MTWAI) values of the PSC patients, if
applicable [26]. The asymptomatic control subjects underwent a screening ileocolonoscopy
for colorectal carcinoma, were negative for all other biochemical and hematological tests,
and presented without any macroscopic or microscopic abnormalities [26].
Ethics statement: This study is a sub-study of the Swiss IBD Cohort Study. Patient
biopsy samples and clinical data collection from patients of the SIBDCS were approved by
the Ethics Committee of the Canton Zürich (KEK-ZH-Nr. 2013-0284). Control data were
retrieved from the Bern Human Intestinal Community project, approved by the Ethics
Commission of the Canton Bern (KEK-BE-Nr 251/14 and 336/14). Informed consent for
data collection and analysis was obtained from all patients of both study cohorts.
DNA extraction: Biopsies were collected in 2 mL microcentrifuge tubes (Sigma-
Aldrich, St. Louis, MO, USA) and stored at −80 ◦C until DNA extraction, as published
previously [21]. Total DNA was isolated using AllPrep DNA/RNA Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. In brief, 600 µL of RLT
lysis buffer (Qiagen), plus β-mercaptoethanol and a metal bead were added into each tube.
Samples were then homogenized using the Retsch Tissue Lyser (Qiagen) at 30/s for 3 min
and 3 min centrifugation at 13,000× g. Total supernatants were transferred into a Prep
DNA mini spin column (Eppendorf, Hamburg, Germany) and centrifuged at 9000× g for
30 s. DNA attached to spin columns was washed and desalted using 500 µL of Buffer AW1
and Buffer AW2 (Qiagen). Total DNA was eluted in 30 µL RNase-free water into 1.5 mL
microfuge tubes. The concentration and purity of the isolated DNA was analyzed using
NanoDrop® (Thermo Fisher Scientific, Waltham, MA, USA).
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16S rRNA sequencing: Amounts of 500 to 1500 ng of DNA per sample were used
to amplify the V5/V6 region of the 16S rRNA gene. The expected product length was
~350 bp including adaptors and barcodes. Bacteria-specific primers (forward 5′ CCATCT-
CATCCCTGCGTGTCTCCGACTCAGC barcode ATTAGATACCCYGGTAGTCC 3′ and
reverse 5′ CCTCTCTATGGGCAGTCGGTGATACGAGCTGACGACARCCATG-3′) were
used [27]. PCR conditions consisted of an initial 5 min at 94 ◦C denaturation step, followed
by 35 cycles of 1 min denaturation at 94 ◦C, 20 s annealing cycle at 46 ◦C, and 30 s extension
cycle at 72 ◦C, with a final extension for 7 min at 72 ◦C. Samples were kept at 4 ◦C until
loading onto a 1% agarose gel. Amplicons were then purified using the Gel Extraction Kit
(Qiagen), and the pooled amplicon library at 26 pM concentration was used for sequenc-
ing, which was performed within the Ion PGMTM System (Thermo Fisher) using an Ion
PGMTM Sequencing 400 Kit and an Ion 316TM Chip V2 [28].
Computation analysis of the 16S rRNA microbial data: Combined FASTQ sequencing
files were first processed in QIIME 1.9.1 pipeline, as described [29] using custom analysis
scripts for analysis on the UBELIX Linux cluster of the University of Bern [26]. Samples
with more than 5000 high-quality reads were then used for downstream analysis in QIIME
and R (R Foundation for Statistical Computing, Vienna, Austria). Operational taxonomic
units were picked using UCLUST with a 97% sequence identity threshold and followed
by taxonomy assignment using the latest Greengenes database (version gg_13_5; green-
genes.secondgenome.com (accessed on 1 February 2021)). The operational taxonomic unit
(OTU) abundance biome file and mapping file were used for statistical analyses and data
was visualized with the phyloseq R package [30]. Species richness within samples was cal-
culated using the α-diversity indices Simpson and Shannon. β-diversity between samples
was calculated using Bray–Curtis genus-level community dissimilarities. Mann–Whitney
U tests were performed for α diversity and Adonis (PERMANOVA) for β diversity was
performed as a statistical test to confirm the strength and statistical significance of groups
in the same distance metrics in the QIIME pipeline and phyloseq in R [30,31]. Taxonomy
profile of samples was performed using multivariate analysis by linear models R pack-
age [32] to find associations between tested groups. The q-value package was implemented
in MaAsLin2 to correct for multiple testing (Benjamini–Hochberg false discovery rate
correction; a false discovery rate (FDR), q-value of 0.2). Taxa present in at least 30% of the
samples and that had more than 0.0001% of total abundance were set as cut-off values
for further analysis. After correction for a false discovery rate, q < 0.05 was considered
significant. Plots were generated with ggplot2 using phyloseq object.
3. Results
A total of 216 biopsy samples taken from the terminal ileum, right colon, left colon, as
well as rectum, were analyzed by 16S rRNA sequencing. All included subjects were male.
Table 1 summarizes the demographics of the included patients.
Table 1. Demographics of study subjects. BMI: body mass index; PSC: primary sclerosing cholangitis;
IBD: inflammatory bowel disease; MTWAI: Modified Truelove and Witts activity index; PTPN2:
protein tyrosine phosphatase nonreceptor type 2.
PSC (N = 7) Non-PSC (N = 42) Non-IBD (N = 28)
BMI
(kg/m2); median (range) 23.8, (21.3–48.8) 23.8, (17.6–35.9) 24.2, (17.3–29.0)
Age at enrollment (year);
median (range) 32, (19–49) 39, (21–58) 41, (20–49)
Smoker at enrollment, N (%) 0 (0%) 6 (14%) 5 (19%)
MTWAI; median, (range) 3, (0–10) 2, (0–9) -
PTPN2 variant: -
TT (N, %) 5, 71% 24, 57%
CT (N, %) 0, 0% 6, 14%
CC (N, %) 0, 0% 1, 2%
Unknown (N, %) 2, 29% 11, 26%
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3.1. Differences in Bacterial Diversity
To obtain an overall impression of the bacterial diversity between groups, samples of
the different locations were pooled and analyzed per patient. Results are given in Figure 1.
α-diversity was higher in PSC patients compared to non-PSC patients and the control
group (Figure 1A). The bacterial community in non-PSC patients and controls clustered
broader than the microbiome of PSC patients (p < 0.001) (Figure 1B).
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shown for pooled samples in non-PSC and non-IBD as indicated. The boxplots represent the median and the interquartile
range. The adj-p value was reported with *** adj-p < 0.001; ** adj-p < 0.01; PSC: primary sclerosing cholangitis; IBD:
inflammatory bowel disease. Non-PSC: n = 94, non-IBD: n = 92.
3.4. PSC Status in UC Results in Minor Taxonomic Changes
All investigated PSC patients suffered from concurrent UC. Hence, to detect micro-
biome changes ssociated solely with PSC, the PSC population was directly compared to
UC patients without PSC (n n-PSC).
When pooling the sampling sites, relative abundance of the genus Bacteroides was
lower, while the abundance of Roseburia was higher in PSC compared to non-PSC (Figure 4).
According to sampling sites, no significant differences at the genus level were detected for
PSC vs. non-PSC at the ileum, right colon, left colon, or rectum.
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3.5. Results According to Genetic Variation of PTPN2
PTPN2 has been discussed as risk gene for PSC [25]. UC patients carrying the C-allele
of the PTPN2 SNP rs1893217 are more likely to have a more severe disease course, including
gallstones—which suggests altered bile acid homeostasis [34]. As the C-allele is rather
rare and was detected in only seven of the investigated patients (see Table 1), microbial
differences between those patients and the wild-type carriers were not detected. However,
after exclusion of the patients carrying the C-allele, the genus Brachyspira was significantly
higher in PSC compared to non-PSC for the pooled sampling sites (p < 0.05; q < 0.05).
When analyzing the data in patients without the PTPN2 C-allele according to the
origin of the biopsy, in the right colon the genus Eubacterium and Tepidimonas were increased
in PSC compared to non-IBD, and Dialister was increased in non-PSC compared to non-IBD
patients. Comparing PSC and non-PSC patients without the C-allele, no differences at the
genus level were detected at the ileum, right colon, left colon, or the rectum.
4. Discussion
This study analyzed the mucosa-associated microbiome of 7 UC patients with PSC
in comparison with 42 UC patients without PSC and 28 controls. PSC patients had an
increased bacterial richness and a shift in the overall microbial composition. This became
apparent in several differences at the genus level detected between groups. By exclusion
of patients with a potentially disease-aggravating genetic variation of the PTPN2 gene, a
significant increase of Brachyspira was detected in biopsies from PSC patients.
PSC patients had a higher Firmicutes/Bacteroidetes (F/B) ratio than UC patients
without PSC and healthy controls (Figure 1). The F/B ratio describes the microbiome on
the phyla level [35]. As those two phyla represent 90% of the gut microbiota, changes
are considered a sign of dysbiosis [36]. An increase in the F/B ratio was associated with
obesity [37]. In IBD and PSC patients, the F/B ratio was reduced in earlier studies [38,39].
The higher ratio in PSC patients might be related to the increase in Roseburia, a genus
belonging to the phylum Firmicutes, detected in the presented study. In addition, earlier
studies found very low rates of Bacteroides [40], which is in line with our findings, and might
add to the increase in the F/B ratio. Bacteroides are producers of sphingolipids, which are
crucial for intestinal homeostasis. A decrease in Bacteroides and therefore sphingolipid levels
resulted in intestinal inflammation [41]. Another genus involved in intestinal pathologies
is Fusobacterium. In our study, Fusobacterium was significantly higher in PSC compared
to non-IBD. Previous studies support this finding as Fusobacterium was overrepresented
in stool samples of PSC patients [17,42]. Furthermore, it is thought that Fusobacterium
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leads to a proinflammatory microenvironment and is ultimately associated with colorectal
cancer [43]. Patients with UC have a high risk of developing these tumors, and this risk is
increased by 30% in patients simultaneously suffering from PSC [44]. Together with the
reduction of Bacteroides (and presumably sphingolipids), the elevation of Fusobacterium
might contribute to this increased cancer risk.
Gut bacteria are involved in bile acid homeostasis [45–47]. Their enzyme bile salt
hydrolase (BSH) deconjugates primary bile acids in the gut [20] and represents one of their
resistance mechanisms against bile acid toxicity [48,49]. A recent study by Quraishi et al.
proved that mucosa-attaching bacterial genera expressing BSH are more abundant in PSC
compared to UC patients without PSC [20]. The presented study detected a significant
increase in the BSH producing genera Roseburia, Haemophilus, and Fusobacterium in PSC
compared to non-IBD patients, Roseburia in PSC compared to UC patients, and Blautia,
Ruminococcus, and Roseburia in UC compared to non-IBD patients. An increase of Roseburia
and Haemophilus in PSC patients was also reported in earlier studies [20]. However, the
BSH-producing genus Bacteroides is significantly lower in PSC compared to UC and non-
IBD patients, which is a known finding in PSC, as mentioned above [40]. Therefore, the
increase in the BSH producers might be a compensatory mechanism for the decrease
in Bacteroides.
We have previously demonstrated that the SNP rs1893217 of the PTPN2 gene (which
introduces a C-allele in the gene) promotes intestinal inflammation as well as a more
severe disease course in IBD [50,51]. Furthermore, in the presence of the PTPN2 variant,
distinct alterations of the mucosa-associated gut microbiome were detected in IBD patients,
suggesting an interplay of genetic risk factors, intestinal microbiota, and disease course [21].
After the exclusion of patients with a C-allele in the PTPN2 gene, Brachyspira was elevated
in PSC versus UC patients in our study. Increased mucosal Brachyspira colonization
has also been detected in patients with irritable bowel syndrome (IBS), especially in IBS
with predominant diarrhea [52]. In IBS, Brachyspira was associated with the induction of
inflammatory mediators in the intestinal mucosa as well as mast cell activation and the
induction of the actin related protein (ARP) 2/3 complex, a protein facilitating bacterial
adhesion and invasion [52]. The ARP2/3 complex is involved in actin nucleation, a crucial
process for cell migration and cytoskeletal motion, which is one of the mechanisms involved
in cancer cell migration [53]. Thus, the subunit 4 (ARPC4) is associated with reduced
survival in patients with hepatocellular carcinoma [54,55]. In addition, the expression
of ARP3 is higher in inflamed intestinal samples of UC patients compared to healthy
controls and it is related to epithelial apoptosis in vitro [56]. In contrast, the inhibition
of the ARP2/3 complex activated the NF-κB pathway, causing a hypersensitive reaction
to osmotic stress, which is associated with IBD [57]. Whether activation of ARP2/3 is
protective or disease-aggravating in PSC, and if Brachyspira contributes to this process,
remains to be elucidated. Analyzing the gut microbiome changes according to sampling
site, the genera Eubacterium and Tepidimonas were significantly higher in the right colon
of PSC patients without the C allele vs. control patients. Eubacterium are butyrate and
BSH-producing bacteria that are associated with beneficial effects on gut and liver [49,58].
This is in line with the assumption that the absence of the PTPN2 risk allele is associated
with a less-severe disease course in IBD [50]. Studies with Tepidimonas are scarce; however,
a recent study detected Tepidimonas in extracellular vesicles of pancreatic tumors [59],
demonstrating a mechanism by which the gut microbiome might influence extraintestinal
organs. Whether this mechanism also applies to PSC, and if it might play a protective, or
rather harmful, role in its pathogenesis is another unanswered question.
Despite the detected microbial differences that can be linked to intestinal and/or bile
duct and liver inflammation, results need to be interpreted with caution, as the number
of PSC patients in this study was rather small. Moreover, the investigated groups slightly
differed in smoking status and BMI range. However, as published previously, smoking
status did not influence the microbiome in UC patients [26].
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5. Conclusions
In conclusion, this study underlines the presence of mucosa-associated microbiome
changes in the gut of patients with PSC. These changes might be indirectly caused by
altered bile acid synthesis or even directly be associated with mucosal inflammation
and periductular fibrosis in PSC. These findings may lay the base for precision medicine
studies investigating the impact of specific bacterial strains in the pathogenesis of PSC. The
presence of a potentially pathogenic gut bacterium in patients without a genetic variation
in PTPN2 rather weakens its role as a risk gene for PSC.
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